FAR-RMS is a large scale trial for children and adults with Rhabdomyosarcoma, a cancer of the soft tissue. The study tests different treatments to see which is most effective at the start and explores new drug combinations for patients whose cancer has returned. The goal is to create a global standard of care that improves survival for all stages of the disease. By testing different radiation doses and chemotherapy combinations in one large study, researchers can more quickly find the best ways to treat this rare cancer and help patients live longer.